A controlled clinical trial was conducted to assess the effectiveness of Oscillococcinum R in the trealment of patients with influenza-like: syndromes. 188 patients received the test drug and 184 patients were assigned to the placebo. Data were recorded by the participating physicians at the beginning of the;: treatment, after 48 hours and after 7-10
Introduction and object of tbe study In medicine • .influenza-like syndromes are of minor importance since this viral disease disappears witttin 5-10 days and usually does not . result in negative consequl!nces. However, the impaired well-being of the patients makes 
Study variables and ,,·twiy period
At the start of the trial, the clinician reco rded the patients' age, gender, weight, other diseases or abnoftnalities, a.dditional medication, rectal temperature and symptoms. After 48 hours, the clinician gavc a g lobal imp ression of the changes in the 'patients' health and recorded any additional prescriptions. At the end of the trial period (after 7-10 days) the clin ician assessed the patients' complianc e and recorded adverse events, as well as abscn' ce of symptoms and the date of fitness fo r work. Standardised questionnaires were used. Twice a day, mornings and evenings, during the fi'rst 5 days of treatment the patients bad to re,l:ord in a jOUITlill their rectal temperature and medication taken, and to rate 9 symptoms (cough, cold, sore throat, muscle pain, erc.) Target variables were: 1) The overali impression of the clinician concerning changes in the patit:nts' health after 48 hours, untl 2) The date of absence of symptoms. Recovery or absence of symptoms wa..'\ defined as '3 reccal tempera~ ture less than 37 .5'C and absence of headache and muscle pain {taken from the patient's daily ' journals)' .
Other variables were: seventy of self~rated symptoms, amount of medication taken, date of return to work and adverse events. The severity of the symptoms of the influenza infection was determined by a totll score. This total score had a vatUI:': ' bc!tween 9 = abst!nl.:e of symptoms (18 = mild, 27 = modernte) and 36 = severe.
Adverse events served as a confidence vari~ able. They were taken from the patients' or the clini cians' records. They gave information on any pathological changes during the time of treatmcnt whether they wcre linked to the active drug or not. Additional variables were premature terminarion of the trial and compli~ ance records.
Medication
The placebo was made of lactose .xnd sacchar~ ?se. It was presl;nted like the active drug (sec mrroJuctlon) in 3 boxes of 3 doses each one dose ·consisted of 200 globules. All pat'ients were asked to take the contents of the rube of medicatio n subiingually, 3 times a day for 3 dnys.
The first dose was administered at the doctor's offic:: but the following doses were: taken by the patients themselves in [he morning. at lunch time and in the t;vening. 
Slatistical hypotheses and experimental study design

Comparison. after 48 hours
After 48 hours, the change til the patient,' condltion· was assessed. At this time point 19.2% of the verum group had no symptom.s and 43.7% bad clearly improved (see Table 2 , Figure I ). In the placebo group, the patients' condition had improved "1C3S. According to the Krauth test, the null hypothesis (the number of patients free of symptoms after ,48 huurs is equal in both treatment groups) was conrradkted at ~a statistically significant leveL The data show a clear improvement in health in the vcrum group. Probability by the Krauth test: P = 0.0028.
Date of absence of symptoms
The second question cUD(;cmed the date of elimination of the symptoms. The statistical analysis was based on the mean date of elimination of symptoms. The proportions of patients with no symptoms were compared after 48 hours. Tht:: distribution is given in Figure 2 . On the morning of the second day, 9.6% of the verwn "group and 1.8% of the placebo group had no symptoms. On the second day, in the evening 17.4% of the verum group and 6.6% of the placebo group were free of symptoms. After 5-day recording of body temperature and influe02aI symptoms, 26.4% of the verum patients and 32.3% of the scores are given by categories (clearl y improved, improved. , .) whkh were defined in the protocol and results presented ( Table 2) .
Severiry of rympw!nS and body remp.,arure
The total <core taken from the patient's journal gives the severity of symptoms. In the verum group, the valuc::'s are lower from 'the first evening compared to the placebo group. The curve ofthededine in individual symptoms runs parallel to the genCIaI trend" as can be seen in Figure 3 which giyes a picrure of the From the first morning of the trial until the fo urth evening, the mean '(alues of the body temperatur~ were (ower in the verum group than in thl! placebo trcarment group. Howe ver, these additional variables do nor provide Jny new infonnation sinct= th ey were parrially included in the target variables .
Concomitant medication
After the first 48 hours, some of the patients in both groups received concomitam medication. Analgesics ilnd anti-rheumatics were [he most frequent. followed by cough medicine and expectorants. Anti-influenzal medication as concomitant therapy played a minor role in both groups." The frequenc), of additional medicallan use was higher i.ll the plcu::ebo group than in the yerum group. Over the! course of the trial the nwnber of patients who received concomitant medication clearly. increased in bOlh groups: in the verum group it increased from 13 .8% to 30.3% and in the placebo group from 8.7% to 36.4%. This difference between the treatment groups continued with the pen::cntiLge ofp<:lrientc; in need of 2 or even 3 concomitant medications:
in the verum group 11.7% of the patients took 2 additional medicines and 2.) % used 3 medica~ lions. In the placebo 16.3% of the patients look 2, additional medicines and 3.3% took 3 diffe~nt preparations.
FiJness fo r work
In the verum group the percentage of patients fit for work was slightly higher throughoul the trial than in the placebo group. I) The decline in symptoms after 48 hours of treatment with the active drug was significantly higher in the vcrurn group than in the placebo group.
2) Symptoms disappeared signi:ficantly f",,'or in the verum group than in the placebo group.
The: resul ts ba!ierl on the patients' journals recording: influenzal symptoms, concomitant 
